|
Interactions: | Acenocoumarol
Adverse Effect: Excessive bleeding
Clinical Management: Concurrent administration of Abciximab and oral anticoagulants, including Acenocoumarol, is contraindicated. Acenocoumarol should not be given within seven days of Abciximab use, unless the patients prothrombin time is less than or equal to 1.2 times control. The combination of Abciximab and oral anticoagulants significantly raises the risk of internal or external haemorrhaging.
Heparin
Adverse Effect: Excessive bleeding
Clinical Management: Before infusing Abciximab, platelet count, prothrombin time and APTT should be measured to identify pre-existing hemostatic abnormalities. During and following Abciximab therapy, platelet counts and the extent of Heparin anticoagulation, as determined by activated clotting time or APTT should be monitored closely.
Hydrochlorthiazide
Concomitant use with Hydrochlorthiazide and Inotropic agents is useful in cardiac failure and with hypertension increase in sensitivity of the drug
Indapamide
Concomitant use with Indapamide and Inotropic agents is useful in cardiac failure and with hypertension increase in sensitivity of the drug
Phenindione
Adverse Effect: Excessive bleeding
Clinical Management: Concurrent administration of Abciximab and oral anticoagulants, including Phenindione, is contraindicated. Phenindione should not be given within seven days of Abciximab use, unless the patients prothrombin time is less than or equal to 1.2 times control. The combination of Abciximab and oral anticoagulants significantly raises the risk of internal or external hemorrhaging.
Warfarin
Adverse Effect: Excessive bleeding
Clinical Management: Concurrent administration of Abciximab and oral anticoagulants, including Warfarin, is contraindicated. Warfarin should not be given within seven days of Abciximab use, unless the patients prothrombin time is less than or equal to 1.2 times control. The combination of Abciximab and oral anticoagulants significantly raises the risk of internal or external hemorrhaging. |
|
|